Pharma Report Profile

1. Gilead Sciences

By

Gilead's current and future success lies in the hands of its antiviral franchise.

2. Johnson & Johnson

By

J&J has earmarked a pile of cash — in the neighborhood of $18.5 billion — for future acquisition targets, but is patiently pacing the sidelines for the best players to walk onto the field.

3. Merck

By

Merck's landmark approval in 2015 was for immunotherapy Keytruda, which was cleared in October as a second-line treatment for the most common form of skin cancer.

4. Novartis

By

There are two primary reasons Novartis anticipates flat sales during 2016: Its hallmark cancer drug Gleevec recently came off patent and its Alcon ophthalmic business has seen declining growth rates.

5. Pfizer

By

Pfizer's dream to shave the top off a rising U.S. tax bill — and level the playing field with overseas competitors — was dashed.

6. AstraZeneca

By

AstraZeneca has embarked on what's likely to be a long, rough ride.

7. Teva

By

Analysts agree that Teva is casting a healthy financial shadow.

8. Amgen

By

As Amgen executives continue to toast a spectacular 2015 performance — double-digit growth from five of eight blockbusters — CEO Robert Bradway has cast a keen eye on the biotech pioneer's future.

9. Roche

By

On the sales and profit forecast front, analysts say that Roche missed the mark in 2015.

10. Sanofi

By

The big news: Sanofi and its partner Regeneron received approval for the first PCSK9 inhibitor to come to market in the U.S.: Praluent. But Praluent's sales to date haven't awed analysts.

11. Allergan

By

Allergan and Pfizer agreed to scrap their pending mega-merger following an early April power play by the U.S. government.

12. AbbVie

By

Coming off what AbbVie's board dubbed an "exceptional year," 2016 may sting.

13. Eli Lilly

By

Diabetes drugs headlined Eli Lilly's 2015 results, with Humalog and Trulicity contributing mightily to the upward sales curve.

14. Novo Nordisk

By

Novo Nordisk wants to own the obesity space much in the same way that it has attempted to dominate diabetes.

15. GlaxoSmithKline

By

The year 2015 was one of restructuring for GlaxoSmithKline.

16. Boehringer Ingelheim

By

In an effort to overcome pricing pressures and bounce back from patent losses, Germany's second-largest drugmaker has unloaded assets and reshuffled its management team.

17. Mylan

By

After turning its back on an offer from generics competitor Teva, Mylan stepped up with an unsuccessful hostile takeover bid for generic drugmaker Perrigo.

18. Biogen

By

Biogen's 2015 was hindered by less-than-stellar sales of its flagship multiple sclerosis treatment Tecfidera.

19. Valeant

By

So, heard anything lately about Valeant? Yeah. Even by the standards of an industry under siege, Valeant experienced quite the tumultuous last year or so.

20. Bristol-Myers Squibb

By

Immuno-oncology was the story at Bristol-Myers Squibb in 2015.

OPINION

Email Newsletters